Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Chairman of Oakwise Capital says wealthy mainland Chinese will continue looking to Hong Kong as a home for their family ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...

In this week’s edition of InnovationRx, we look at how Daniel Nadler became a billionaire building a ChatGPT for doctors, big ...

Morgans healthcare and life sciences expert Iain Wilkie explains what the movers and shakers have been doing in health and ...

Get the latest HENGRUI PHARMA (600276.SS) stock news and headlines to help you in your trading and investing decisions.

Briefing documents were disclosed relating to the meeting of the U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC), which will convene July 17 on the matter of London-based GSK plc’s Blenrep ...

Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...

HONG KONG] A parade of China’s mega listings in Hong Kong since the turn of the year has helped restore some of the shine to the city as the world’s largest fundraising destination for initial public ...